Drug intelligence / Profile preview

MGT-006

Development stage: Unknown
Lead developer: Metagen Therapeutics
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

MGT-006 is an investigational oral microbiome therapy developed by Metagen Therapeutics for the treatment of moderately active ulcerative colitis. As a live biotherapeutic product, it consists of a defined or donor-derived microbial consortium encapsulated for oral delivery, aimed at restoring intestinal dysbiosis and modulating the mucosal immune response. The drug is currently undergoing Phase 1b/2a clinical evaluation in Japan and the United States, focusing on safety, tolerability, and the successful engraftment of therapeutic bacteria within the patient's gut microbiome.

Beyond the preview

Go deeper on MGT-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MGT-006.

Explore the full profile